Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 18/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 7/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.48 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2341524 | 0.83 | MAPT (0.54) | KMT2ACA1CA2 | |
| SCHEMBL9211504 | 0.81 | TDP1 (0.46) | ALDH1A1KMT2ACA1CA2 | |
| SCHEMBL9220566 | 0.79 | MMP13 (0.48) | ALDH1A1KMT2ACA1CA2 | |
| SCHEMBL5238412 | 0.78 | SSTR5 (0.39) | — | |
| SCHEMBL10345075 | 0.78 | DRD2 (0.50) | ALDH1A1KMT2A | |
| SCHEMBL2343249 | 0.78 | OPRM1 (0.41) | ALDH1A1MAOB | |
| Hydrochloric Acid SCHEMBL7981065 | 0.76 | OPRM1 (0.40) | ALDH1A1 | |
| SCHEMBL6285915 | 0.75 | MAPT (0.50) | ALDH1A1KMT2AMAOBAOC3 | |
| SCHEMBL6728043 | 0.74 | PARP10 (0.47) | PARP10PARP15PARP2ALDH1A1 | |
| SCHEMBL6284574 | 0.72 | KCNH2 (0.49) | PARP10PARP15PARP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956046-B2 | 4-hydroxypiperidine derivatives having analgesic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1391452-A1 | 4-HYDROXPIPERIDINE DERIVATIVE WITH ANALGETIC ACTIVITY | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | HNMT, HDAC1, HDAC3 | PARP10 3017/4885PARP15 3405/4885PARP2 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.